Patient-reported outcome measures have become a pivotal aspect of value-based care. As this is increasingly considered in the implementation of value-based healthcare, there are several practice-changing studies targeted at demonstrating the safety of these changes.
In patients with high-risk gene positive variants for breast cancer, there has long been a clinician preference for skin sparing mastectomy (SSM) over nipple-sparing mastectomy (NSM) for a number of reasons including inconclusive evidence regarding the oncological safety of NSM.
Studies have shown that patient-reported outcome measures are greater with NSM. We aim to participate in a multi-centre, international retrospective cohort study to confirm that NSM is a safe and effective risk reducing strategy for patients with high-penetrance breast cancer genes.
In establishing the oncological safety of risk-reducing surgery in nipple-sparing mastectomy for high-penetrance germline variants, we can better inform patients regarding the options for risk-reduction.
